HUP0500332A3 - Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them - Google Patents

Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them

Info

Publication number
HUP0500332A3
HUP0500332A3 HU0500332A HUP0500332A HUP0500332A3 HU P0500332 A3 HUP0500332 A3 HU P0500332A3 HU 0500332 A HU0500332 A HU 0500332A HU P0500332 A HUP0500332 A HU P0500332A HU P0500332 A3 HUP0500332 A3 HU P0500332A3
Authority
HU
Hungary
Prior art keywords
pyrimidin
pyrimidinyl
tetrahydropyrimido
dihydroimidazo
derivatives
Prior art date
Application number
HU0500332A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01402431A external-priority patent/EP1295884A1/en
Priority claimed from EP02290488A external-priority patent/EP1340760A1/en
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Publication of HUP0500332A2 publication Critical patent/HUP0500332A2/hu
Publication of HUP0500332A3 publication Critical patent/HUP0500332A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
HU0500332A 2001-09-21 2002-09-19 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them HUP0500332A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01402431A EP1295884A1 (en) 2001-09-21 2001-09-21 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP02290488A EP1340760A1 (en) 2002-02-28 2002-02-28 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
PCT/EP2002/011127 WO2003027115A1 (en) 2001-09-21 2002-09-19 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders

Publications (2)

Publication Number Publication Date
HUP0500332A2 HUP0500332A2 (hu) 2005-07-28
HUP0500332A3 true HUP0500332A3 (en) 2009-12-28

Family

ID=26077255

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500332A HUP0500332A3 (en) 2001-09-21 2002-09-19 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them

Country Status (23)

Country Link
US (2) US7388005B2 (https=)
EP (1) EP1430056B1 (https=)
JP (2) JP4570361B2 (https=)
KR (1) KR100868840B1 (https=)
CN (1) CN1247586C (https=)
AR (1) AR036599A1 (https=)
AT (1) ATE307815T1 (https=)
AU (1) AU2002342798C1 (https=)
BR (1) BR0212904A (https=)
CA (1) CA2457952C (https=)
CY (1) CY1105553T1 (https=)
DE (1) DE60206946T2 (https=)
DK (1) DK1430056T3 (https=)
EA (2) EA007165B1 (https=)
ES (1) ES2250721T3 (https=)
HU (1) HUP0500332A3 (https=)
IL (2) IL160397A0 (https=)
MX (1) MXPA04002632A (https=)
NO (1) NO329566B1 (https=)
NZ (1) NZ531244A (https=)
PL (1) PL370535A1 (https=)
SI (1) SI1430056T1 (https=)
WO (1) WO2003027115A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454909B1 (en) * 2003-03-07 2008-08-20 Sanofi Aventis 8'-pyridinyl-dihydrospiro- (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one derivatives and their use against neurodegenerative diseases
EP1557417B1 (en) * 2003-12-19 2007-03-07 Sanofi-Aventis Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
WO2005070932A2 (en) 2004-01-22 2005-08-04 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2006259675A1 (en) * 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP1992621A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992620A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en) 2007-05-16 2008-11-19 Sanofi-Aventis Arylamide pyrimidone compounds
EP1992624A1 (en) * 2007-05-16 2008-11-19 Sanofi-Aventis Heteroarylamide pyrimidone compounds
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
EP2085400A1 (en) * 2008-01-29 2009-08-05 Sanofi-Aventis Substituted heteroarylamide oxazepinopyrimidone derivatives
EP2090578A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta
EP2085399A1 (en) * 2008-01-29 2009-08-05 Sanofi-Aventis substituted arylamide oxazepinopyrimidone derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138492A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8421890B2 (en) 2010-01-15 2013-04-16 Picofield Technologies, Inc. Electronic imager using an impedance sensor grid array and method of making
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP7403351B2 (ja) 2020-02-27 2023-12-22 三菱重工業株式会社 通信ポイント決定装置、通信ポイント決定方法およびプログラム、並びに点検システム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865836A (en) * 1972-12-08 1975-02-11 Janssen Pharmaceutica Nv Bicyclic imidazoles
SU600143A1 (ru) * 1976-12-06 1978-03-30 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср Способ получени гетероциклических систем, содержащих бормзамещенный имидазол
JPS63216886A (ja) * 1987-03-05 1988-09-09 Sumitomo Chem Co Ltd ピリミドピリミジン誘導体およびその製造法
JP2862958B2 (ja) * 1990-06-09 1999-03-03 三協化学株式会社 感熱転写記録用色素
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
EP0948496A2 (en) 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
EA200000840A1 (ru) * 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments

Also Published As

Publication number Publication date
JP2010189422A (ja) 2010-09-02
DE60206946T2 (de) 2006-07-27
ES2250721T3 (es) 2006-04-16
HK1091495A1 (zh) 2007-01-19
EA007165B1 (ru) 2006-08-25
PL370535A1 (en) 2005-05-30
WO2003027115A1 (en) 2003-04-03
BR0212904A (pt) 2004-10-13
IL160397A (en) 2009-07-20
SI1430056T1 (sl) 2006-02-28
NO20041142L (no) 2004-06-21
CN1247586C (zh) 2006-03-29
CA2457952C (en) 2009-11-10
CN1556810A (zh) 2004-12-22
EA009456B1 (ru) 2007-12-28
EP1430056B1 (en) 2005-10-26
AU2002342798C1 (en) 2008-09-25
CY1105553T1 (el) 2010-07-28
JP2005504809A (ja) 2005-02-17
EA200400236A1 (ru) 2004-10-28
HUP0500332A2 (hu) 2005-07-28
KR100868840B1 (ko) 2008-11-14
KR20040039390A (ko) 2004-05-10
DE60206946D1 (de) 2005-12-01
IL160397A0 (en) 2004-07-25
ATE307815T1 (de) 2005-11-15
EA200600196A1 (ru) 2006-08-25
US7388005B2 (en) 2008-06-17
JP4570361B2 (ja) 2010-10-27
EP1430056A1 (en) 2004-06-23
AU2002342798B2 (en) 2008-01-10
NZ531244A (en) 2006-06-30
NO329566B1 (no) 2010-11-15
US20080269257A1 (en) 2008-10-30
US7781440B2 (en) 2010-08-24
MXPA04002632A (es) 2004-07-08
DK1430056T3 (da) 2006-02-27
AR036599A1 (es) 2004-09-22
CA2457952A1 (en) 2003-04-03
US20040266793A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0401047A3 (en) Triazolo[4,5-d]pyrimidine derivatives, their use as purinergic receptor antagonist and pharmaceutical compositions containing same
IL128869A (en) ARYSULFONYL-SUBSTITUTED-PYRAZOLO [1,5-a]-PYRIMIDINE AND PYRAZOLO [1,5-a] [1, 3, 5]-TRIAZINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0303350A3 (en) Use of substituted imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and imidazo[1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting pharmaceutical compositions
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0200207A3 (en) Substituted 2-aryl-3-(hetroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compositions and methods for their preparation
IL220174A (en) Acidic Salts of 5-Amino History- {Pyrazolo [3,4- e] –4,2,1- Triazolo [5,1– c] pyrimidine} preserved in positions 2 and 7 and pharmaceutical preparations coating them
IL191960A (en) History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
HUP0105081A3 (en) Triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
IL151849A0 (en) Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides
HUP0202494A2 (en) Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0203131A3 (en) Amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
HUP0402324A3 (en) [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
AU1224902A (en) 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
HUP9904434A3 (en) Use of pyrazolo[4,3-d]pyrimidinones, quinazolinones, purinones pyrido[3,2-d]pyrimidinones for the preparation of pharmaceutical compositions treating nitrate-induced tolerance
HUP0400743A3 (en) Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives, process for their preparation and pharmaceutical conpositions containing them
IL156536A0 (en) Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
AU2002361407A1 (en) Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof
IL144156A0 (en) Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
SI1480981T1 (sl) Derivati 1-(alkil), 1-(heteroaril)alkil- in 1-(aril)alkil)-7-(pirimidin-4-il)-imidazo(1,2-alfa)pirimidin-5(1H)-ona
HUP0303138A3 (en) Pyrrolo[3,4-d]pyrimidines as corticotropin releasing factor (crf) antagonists, pharmaceutical compositions containing them and their use
PL362408A1 (en) Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
PL366437A1 (en) Use of substituted imidazo 1,2-a]-pyridine-3-yl-amide and imidazo 1,2-a]-pyridine-3-yl-amine compounds as medicaments

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees